Treatment of postmenopausal osteoporosis
Key points
- The most devastating outcome of Osteoporosis is fracture, which results in increased morbidity and mortality.
- Moreover, because Osteoporosis is a chronic condition requiring long-term therapy, factors that increase compliance and improve safety and efficacy outcomes should be considered when treatment is selected.
- Raloxifene decreases the risk of nonvertebral fracture, but only in women with severe prevalent vertebral fractures.
- Therefore, clinicians and patients have several options for reducing the risk of fracture and achieving optimal dosing convenience.
Osteoporosis is a major public health burden.
The most devastating outcome of Osteoporosis is fracture, which results in increased morbidity and mortality. These fractures most often occur in the vertebrae and indicate an increased risk of future vertebral and hip fractures. Consequently, it is important to identify patients at risk for fracture and to intervene with pharmacologic therapies, lifestyle changes, or both to reduce the frequency of the first or subsequent fracture.
Moreover, because Osteoporosis is a chronic condition requiring long-term therapy, factors that increase compliance and improve safety and efficacy outcomes should be considered when treatment is selected. The bisphosphonates alendronate and risedronate can substantially reduce the risk of both hip and vertebral fractures. Furthermore, these agents are available in once-weekly formulations that provide patients with a convenient alternative to a daily dosage regimen. Alendronate and the selective estrogen-receptor modulator raloxifene provide considerable vertebral fracture protection after 1 year of treatment, and risedronate markedly reduces the rate of vertebral and nonvertebral fractures after 6 months of treatment. Data suggest that calcitonin-salmon nasal spray also reduces the risk of vertebral, but not nonvertebral, fractures.
Raloxifene decreases the risk of nonvertebral fracture, but only in women with severe prevalent vertebral fractures. Although evidence supports the efficacy of hormone therapy, the risks should be carefully considered before treatment is begun. In addition to the antiresorptive therapies, teriparatide is a daily injectable anabolic treatment that is effective in reducing the risk of vertebral and nonvertebral fractures.
Therefore, clinicians and patients have several options for reducing the risk of fracture and achieving optimal dosing convenience.
Fosamax Fosamax/Alendronate is used to prevent and treat postmenopausal osteoporosis (bone weakening) or Paget's disease. Fosamax prevents or slows weakening of bone.
More information about Fosamax » »
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Women's Health →
NewsOsteoporosis is a major threat to women and their future independence, new report warns
According to a new report published today by the International Osteoporosis Foundation (IOF), women may expect to live longer but their quality of life will be seriously jeopardized if action to protect their bone…
11 October 2013
NewsBritish women 50 percent less likley to receive treatment for common menopausal symptoms
New data, published today in Menopause International, suggests that post-menopausal women in Britain are experiencing less sex, and less satisfying sex compared to their European and North American counterparts, because…
20 June 2013
NewsTestosterone improves verbal learning and memory in postmenopausal women
Postmenopausal women had better improvement in verbal learning and memory after receiving treatment with testosterone gel, compared with women who received sham treatment with a placebo, a new study found. Results were…
